Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Phase 1

Completed

Conditions: Scalp Psoriasis

Interventions: Drug: Betamethasone Scalp Suspension 0.064%;0.0005%
Drug: Placebo topical suspension
Drug: Taclonex®

First Posted Date: 2019-03-19

Last Posted Date: 2019-03-19

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 485

Registration Number: NCT03880357

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: HAT1
Drug: Calcipotriol

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Haus Bioceuticals

Target Recruit Count: 174

Registration Number: NCT03848806

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Enstilar

First Posted Date: 2019-02-21

Last Posted Date: 2020-08-26

Lead Sponsor: Derm Research, PLLC

Target Recruit Count: 20

Registration Number: NCT03848871

Locations: 🇺🇸
DermResearch, PLLC, Louisville, Kentucky, United States

Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata

Not Applicable

Completed

Conditions: Alopecia Areata

Interventions: Device: Narrow Band UVB
Drug: Calcipotriol
Diagnostic Test: vitamin D3 level

First Posted Date: 2019-02-20

Last Posted Date: 2019-04-02

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 60

Registration Number: NCT03847441

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Phase 4

Recruiting

Conditions: Psoriasis

Interventions: Drug: Enstilar 0.005%-0.064% Topical Foam

First Posted Date: 2019-02-04

Last Posted Date: 2019-02-04

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 30

Registration Number: NCT03827876

Locations: 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Phase 3

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO 90100 foam
Drug: Dovobet® ointment

First Posted Date: 2019-01-16

Last Posted Date: 2025-03-10

Lead Sponsor: LEO Pharma

Target Recruit Count: 182

Registration Number: NCT03806790

Locations: 🇯🇵
Leo Pharma Investigational Site, Setagaya, Tokyo, Japan

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Phase 3

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
Other: Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug: Enstilar® foam (LEO Pharma Inc.)

First Posted Date: 2018-11-06

Last Posted Date: 2020-08-19

Lead Sponsor: Glenmark Pharmaceuticals Ltd. India

Target Recruit Count: 494

Registration Number: NCT03731091

Locations: 🇺🇸
Investigational Site 20, Encinitas, California, United States
🇺🇸
Investigational Site 18, Fountain Valley, California, United States
🇺🇸
Investigational Site 28, New York, New York, United States

and more 27 locations

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Topical Calcipotriene Ointment
Other: Topical Vaseline

First Posted Date: 2018-07-23

Last Posted Date: 2025-05-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 43

Registration Number: NCT03596073

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Phase 4

Completed

Conditions: Psoriasis
Plaque Psoriasis

Interventions: Drug: Vehicle foam
Drug: Enstilar® foam

First Posted Date: 2018-04-24

Last Posted Date: 2021-01-20

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 25

Registration Number: NCT03506477

Locations: 🇺🇸
Mount Sinai West, New York, New York, United States

Dermatopharmacokinetic Trial of LEO 90100 Foam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LEO 90100 foam
Drug: Dovobet® ointment

First Posted Date: 2018-03-26

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 58

Registration Number: NCT03476746

Locations: 🇯🇵
Investigational site, Fukuoka, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy